

EACR

European Association  
for Cancer Research

CONFERENCES

[www.eacr.org](http://www.eacr.org)

EACR Conference

# Cancer Metabolism

08-10 October 2024 | Bilbao, Spain

## Scientific Programme Committee

Arkaitz Carracedo

Karen Vousden

Matthew Vander Heiden    Alexia-Ileana Zaromytidou

Scan the QR code to access online conference  
resources, including speaker and poster abstracts

[eacr.org/conference/cancermetabolism2024](http://eacr.org/conference/cancermetabolism2024)



# Save the date

[eacr.org/conference](https://eacr.org/conference)



EACR Conference

## LIQUID BIOPSIES

**Lyon, France**

12 - 14 November 2024

EACR Conference

## CANCER AND AGEING

**Virtual event**

03 - 04 December 2024

EACR-AstraZeneca Conference

## CIRCULATING NUCLEIC ACIDS (cfDNA/ctDNA)

IN USE, IN VIEW AND  
ON THE HORIZON

**Virtual event**

28 - 29 January 2025

EACR-Boehringer Ingelheim Conference

## DRUGGING AND REGULATING THE MAP KINASE PATHWAY

**Virtual event**

11 - 12 February 2025

EACR Conference

## THE SYSTEMIC CONSEQUENCES OF CANCER: Cancer as a Whole-body Disease

**Virtual event**

25 - 26 February 2025

EACR Conference

## PERSISTENT CELLS: from Bacteria to Cancer

**Lyon, France**

18 - 20 March 2025



16-19 June 2025

Lisbon, Portugal

Join us for the EACR  
Annual Congress

**[2025.eacr.org](https://2025.eacr.org)**

# Cancer Metabolism

Tag us  @EACRnews  @helloeacr | Wi-Fi: CM2024 | Password: EACRBilbao

## Day 1 | Tuesday 08 October

Posters 1-117  
can be put up

From 11:30

### REGISTRATION

12:00-13:00

### WELCOME LUNCH

*A chance to meet fellow attendees and enjoy a light buffet lunch*

13:00-13:10

### CONFERENCE WELCOME Scientific Programme Committee

### SESSION 1: METABOLIC SIGNALLING IN CANCER

Chair: Arkaitz Carracedo

13:10-13:40

Q&A: 13:40-13:55

### OPENING KEYNOTE LECTURE

**Eileen White** Rutgers Cancer Institute of New Jersey, USA  
'Metabolic alterations driving cancer cachexia'

13:55-14:15

Q&A: 14:15-14:25

**Naama Kanarek** Harvard Medical School, USA  
'Metabolic Vulnerabilities of Leukemia that Spreads to the Central Nervous System'

14:25-14:35

Q&A: 14:35-14:40

**Naiara Santana Codina** Aarhus University, Denmark  
Proffered Paper 1: 'Defining and Targeting Mechanisms of Acquired Resistance to Nucleotide Synthesis Inhibition in Pancreatic Cancer'

14:40-14:50

### EXHIBITOR INTRODUCTIONS

*60-second intro pitches by each company*

14:50-15:20

### COFFEE BREAK, EXHIBITION & SOLO MEET-UP

*Solo travellers are invited to meet up at the EACR banner in the exhibition hall to connect with fellow adventurers.*

15:20-15:30


Q&A: 15:30-15:35

**Nicla Lorito** University of Florence, Italy  
Proffered Paper 2: 'FADS1/2-mediated lipid metabolic reprogramming drives ferroptosis sensitivity in metastatic triple negative breast cancer'


15:35-15:55

Q&A: 15:55-16:05

**Arkaitz Carracedo** CIC Biogune, Spain  
'Post-transcriptional control of metabolism (and viceversa) in cancer and beyond'

16:05-16:15 Q&A: 16:15-16:20	<b>Mónica Cremades Rodelgo</b> CECAD, Germany Proffered Paper 3: 'The link between mitochondrial ultrastructure and innate immune response upon Fumarate Hydratase loss'
16:20-16:30	<b>POSTER SPOTLIGHTS</b> <i>Posters 1, 40 and 80 will be presented in short 3-minute 'flash talks'</i>
16:30-17:00	<b>GEMPHARMATECH SYMPOSIUM</b> <b>Xiangli Bian</b> Project Manager, GemPharmatech Co., Ltd 'KOAP: Genetically Modified Mouse Models and Applications'
17:00-17:30	<b>MEET THE EXPERTS</b> <b>Naama Kanarek and Marcus Goncalves</b> <i>An informal session where panellists will each share their own personal and professional experiences of their paths to scientific leadership.</i>
17:30-18:15	 <b>WELCOME RECEPTION</b> <i>with drinks and a light buffet</i>
18:15-19:45	<b>POSTER DISCUSSION SESSION 1</b> <i>Presenters of posters 1-117 should stand by their boards</i>

## Day 2 | Wednesday 09 October

08:15-08:45	 <b>EARLY POSTER VIEWING WITH COFFEE</b>
	Chair: Matt Vander Heiden
08:45-09:00	<b>AGILENT TECHNOLOGIES SPOTLIGHT</b> <b>Alfredo Caro-Maldonado</b> Seahorse-RTCA xCelligence Field Application Scientist, Agilent Technologies 'Advanced Tools for Cell Therapy Research and Development'
	<b>SESSION 2: METABOLIC CROSS TALK WITH THE TUMOUR MICROENVIRONMENT</b>
09:00-09:20 Q&A: 09:20-09:30	<b>Elisabeth Letellier</b> University of Luxembourg, Luxembourg 'De-coding microbial metabolism in cancer'
09:30-09:40 Q&A: 09:40-09:45	<b>Petra Hyrossova</b> Czech Academy of Sciences, Czech Republic Proffered Paper 4: 'Endothelial pyrimidine synthesis deficiency promotes tumor growth'
09:45-10:05 Q&A: 10:05-10:15	<b>THE EMBO KEYNOTE LECTURE</b> <b>Karen Vousden</b> The Francis Crick Institute, UK 'Metabolic crosstalk between the tumour and the host'



10:15-10:35  
Q&A: 10:35-10:45

10:45-11:15

11:15-11:35  
Q&A: 11:35-11:45

11:45-11:55  
Q&A: 11:55-12:00

12:00-12:30

12:30-13:30

13:30-15:10

15:00-15:20  
Q&A: 15:20-15:30

15:30-15:40  
Q&A: 15:40-15:45

15:45-15:55  
Q&A: 15:55-16:00

16:00-16:30

16:30-16:50  
Q&A: 16:50-17:00

17:00-17:20  
Q&A: 17:20-17:30

**Payam Gammage** Cancer Research UK Scotland Institute, UK  
'Redox imbalance and anti-tumour immunity'



## COFFEE BREAK & EXHIBITION

**Wilhelm Palm** DKFZ, Germany  
'Metabolic stress adaptations in cancer'

**Peio Azcoaga** BIODONOSTIA, Spain  
Proffered Paper 5: 'Oncostatin M cytokine signalling orchestrates immune remodelling and metabolism within the breast tumour microenvironment'

## POSTER SPOTLIGHTS

*Posters 120, 125, 130, 160, 200, 220 and 228 will be presented in short 3-minute 'flash talks'*



## LUNCH & EXHIBITION

## POSTER DISCUSSION SESSION 2

*Presenters of posters 118-236 should stand by their boards*

## SESSION 3: METABOLIC PROCESSES THAT INFLUENCE CANCER PROGRESSION AND TREATMENT

Chair: Alexia-Ileana Zaromytidou

**Martin Bergh** Karolinska Institutet, Sweden  
'Antioxidants stimulate blood flow in tumours'

**Paula Duch** Cancer Research UK Scotland Institute, UK  
Proffered Paper 6: 'Harnessing epigenetics to reprogram cancer-associated fibroblasts in metastatic breast cancer'

**Hamza Furkan Alkan** UT Southwestern Medical Center, USA  
Proffered Paper 7: 'Metabolic Regulation of Melanoma Immunogenicity and Metastasis'



## COFFEE BREAK & EXHIBITION

**KJ Patel** University of Oxford, UK  
'Endogenous formaldehyde – a toxic metabolic source and modulator of 1 Carbon metabolism'

**Patricia Altea Manzano** Cabimer, Spain  
'Emerging roles of fatty acid metabolism in metastasis'

Take down  
posters 1-117

Posters 118-236  
can be put up

17:30-18:15

## MEET THE EDITORS

Join us in this session led by Dr Alexia-Ileana Zaromytidou, Chief Editor at Nature Cancer, to hear advice about the world of publishing in a relaxed and informal setting.

20:00



## OPTIONAL CONFERENCE DINNER (SOLD OUT)

The conference dinner will take place at Kafe Antzokia Restaurant followed by a DJ and dancing (separate ticketed event - sold out)

## Day 3 | Thursday 10 October

08:15-08:45



## EARLY POSTER VIEWING WITH COFFEE

Chair: Karen Vousden

08:45-09:00

## CANCERTOOLS.ORG SPOTLIGHT

**Dr Seema Sharma** CancerTools.org

'A transformative approach to support cancer researchers'

## SESSION 4: SYSTEMIC METABOLIC CHANGES AND CANCER PROGRESSION

09:00-09:20

**Marcus Goncalves** Weill Cornell Medicine, USA

Q&A: 09:20-09:30

'Lung cancer induced metabolic derangements driving cachexia'

09:30-09:50

**Alejo Efeyan** CNIO, Spain

Q&A: 09:50-10:00

'Nutrient signaling in cancer cells and in the stroma – the Goldilocks effect'

10:00-10:10

**Raphael Morscher** University Children's Hospital Zürich, Switzerland

Q&A: 10:10-10:15

Proffered Paper 8: 'Reprogramming neuroblastoma by diet-enhanced polyamine depletion'

10:15-10:45



## COFFEE BREAK & EXHIBITION

10:45-11:05

**Matthew Vander Heiden** Koch Institute, USA

Q&A: 11:05-11:15

'The influence of metabolism on cancer progression'

11:15-11:45

## CLOSING KEYNOTE LECTURE

**Ayelet Erez** Weizmann Institute of Science, Israel

Q&A: 11:45-12:00

'Exploring the tumor Macro-environment to improve cancer diagnosis and therapy'

12:00

## SUMMARY, AWARDS AND DEPART

# Travel grants

More information about EACR grants: [eacr.org/travel-grant](https://eacr.org/travel-grant)

**EACR-Worldwide Cancer Research** Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Travel Grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- ROJA BARUWAL, USA
- AVISHY MALIACH, ISRAEL
- ARUNDHATHI DEV J R, INDIA
- FARID NETO, BRAZIL
- PAULA DUCH, UK
- DEBARATI SANYAL, GERMANY
- ELLA-MAY HARDS, UK
- TIM VAN TIENHOVEN, NETHERLANDS
- NICLA LORITO, ITALY

**EACR**  
European Association  
for Cancer Research

**worldwide  
cancer  
research**

## Supporters

Our thanks to the following partners for supporting us in promoting this conference:




We would also like to thank the following grant providers:



This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.

# Venue floor plan



## Exhibitors

- |                    |                   |                        |
|--------------------|-------------------|------------------------|
| 1. NVision         | 5. MedChemExpress | 9. CeGaT               |
| 2. Agilent         | 6. Tebubio        | 10. Sable Systems      |
| 3. Panome Bio      | 7. VectorBuilder  | 11. IDEXX BioAnalytics |
| 4. CancerTools.org | 8. GemPharmatech  |                        |

# Meet the Exhibitors

## **NVision** Stand: 1

**Website:** [www.nvision-imaging.com](http://www.nvision-imaging.com)

**Represented at the conference by:**

Irina Heid, Sella Brosh

NVISION

## **Agilent Technologies** Stand: 2

**Website:** [www.agilent.com](http://www.agilent.com)

**Represented at the conference by:**

Alfredo Caro-Maldonado, Yolanda Sánchez, Miriam Contreras

**Spotlight:** Wednesday 09 October 2024 | 08:45-09:00

Alfredo Caro-Maldonado: 'Advanced Tools for Cell Therapy Research and Development'



## **Panome Bio** Stand: 3

**Website:** [www.panomebio.com](http://www.panomebio.com)

**Represented at the conference by:**

Kurt Herrenknecht



## **CancerTools.org** Stand: 4

**Website:** [www.cancertools.org](http://www.cancertools.org)

**Represented at the conference by:**

Abby Henney, Roxana Sava, Robert Bondaryk

**Spotlight:** Thursday 10 October 2024 | 08:45-09:00

Dr Seema Sharma: 'A transformative approach to support cancer researchers'



## **MedChemExpress** Stand: 5

**Website:** [www.medchemexpress.com](http://www.medchemexpress.com)

**Represented at the conference by:**

Sayuri Xiong, Paola Vecino



## **Tebubio** Stand: 6

**Website:** [www.tebubio.com](http://www.tebubio.com)

**Represented at the conference by:**

Cristina Peral Perez, Paula Perez



# Meet the Exhibitors

## **VectorBuilder** Stand: 7

**Website:** [en.vectorbuilder.com](http://en.vectorbuilder.com)

**Represented at the conference by:**

Sandra Akpe San Roman



## **GemPharmatech** Stand: 8

**Website:** [en.gempharmatech.com](http://en.gempharmatech.com)

**Represented at the conference by:**

Lin Wenxuan, Xiangli Bian, Liu Xinyu

**Symposium:** Tuesday 08 October 2024 | 16:30-17:00

Xiangli Bian: 'KOAP: Genetically Modified Mouse Models and Applications'



## **CeGaT** Stand: 9

**Website:** [www.cegat.com](http://www.cegat.com)

**Represented at the conference by:**

Ana Bento, Sami Azrak



## **Sable Systems** Stand: 10

**Website:** [www.sablesys.com](http://www.sablesys.com)

**Represented at the conference by:**

Lars Breuer



## **IDEXX BioAnalytics** Stand: 11

**Website:** [www.idexxbioanalytics.com](http://www.idexxbioanalytics.com)

**Represented at the conference by:**

Marianne Lagache, David Mayo





# Poster index

View abstracts when logged-in at [www.eacr.org/conference/cancermetabolism2024](http://www.eacr.org/conference/cancermetabolism2024)

- 1 **[POSTER SPOTLIGHT]** Understanding the Role of Mtdna Alterations and Electron Transport Chain Function in Thyroid Cancer Presented by Celia de la Calle Arregui, University of Texas Southwestern Medical Center, Dallas, USA
- 2 Serum insulin-like growth factor-related molecules and colorectal cancer risk by tumor location: a nested case-control study Presented by Yasushi Adachi, Sapporo Shirakaba-dai Hospital, JAPAN
- 3 Investigating the role of ShcD in the metabolomics of U87MG glioma cells: Could it explain its oncogenic activity? Presented by Samrein Ahmed, Sheffield Hallam University, UK
- 4 ChREBP-mediated regulation of galectin-9 expression decreases tumor associated macrophages anti-cancer immune response to favor HCC development Presented by Sylvain Albanet, Institut Cochin, Paris, FRANCE
- 5 Metabolic rewiring in pyrimidine synthesis deficient lung cancer cells Presented by Ahmad Alghadi, Czech Academy of Science and Charles University, Prague, CZECH REPUBLIC
- 6 Glucose promotes breast cancer cell stemness and aggressiveness by modulating the interaction with mammary adipose tissue-derived mesenchymal stem cells Presented by Maria Rosaria Ambrosio, IEOS-CNR, Naples, ITALY *[SESSION 2]*
- 7 A metabolic crosstalk between liposarcoma and muscle sustains tumor growth Presented by Alix Amsel, Montpellier Cancer Research Institute , FRANCE
- 8 Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX models Presented by Eleonora Angi, IOV-IRCCS, Padova, ITALY
- 9 IGF1Rs regulate the Metabolic Phenotype of Cancer Associated Fibroblasts Presented by Sharath Chandra Arandkar, Tata Memorial Centre-ACTREC, Navi Mumbai, Maharashtra, INDIA
- 10 Functional genomics approaches uncover distinct metabolic dependencies in renal cell carcinoma Presented by Michael Aregger, NCI, NIH, Frederick, MD, USA
- 11 Impact of Physiological Media in Jurkat Metabolism and the Response to Chemotherapy Presented by Andrea Armero, Instituto de Investigación Sanitaria La Fe, Valencia, SPAIN
- 12 The antidiabetic PPAR agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. Presented by Emine Atas, Medical University of Vienna, AUSTRIA
- 13 Enhanced Sensitivity of Cancer Cells with Increased Mitochondrial Activity to Copper Ionophore Neocuproine Presented by Jana Bachmann, University Hospital of Zurich and University of Zurich, SWITZERLAND
- 14 Investigating the role of fumarate in cancer cells with optical imaging Presented by Seema Bachoo, University of Cambridge, UK
- 15 PCSK9 metabolic implications in metastatic and non-metastatic colorectal cancer Presented by Iker Badiola, University of the Basque Country, Bizkaia, SPAIN

- 16 Systemic impact of metastasis over host metabolism Presented by Eleonora Barone, IRB Barcelona, SPAIN
- 17 Investigating alterations in the metabolic profile of ovarian cancer-associated stroma Presented by Roja Baruwat, University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, PA, USA
- 18 Tamoxifen resistance in breast cancer is associated with activation of GPR55 signaling and production of lysophospholipids in mitochondria Presented by Kamila Baslarová, Czech Academy of Sciences, Prague, CZECH REPUBLIC
- 19 Lovastatin Synergizes with GOT1 inhibitor to Kill Cancer Cells Presented by Elif Bayram, Bursa Uludag University, Nilufer, TURKEY
- 20 Using 5-aminosalicylic acid (5-ASA) to prevent metabolic reprogramming required for colorectal tumour progression Presented by Katherine Belfield, University of Bristol and University Hospitals Bristol and Weston, BRISTOL, UK
- 21 Immunosuppressive Activity of Methylglyoxal Within the Breast Cancer Microenvironment Presented by Akeila Bellahcene, University of Liège, BELGIUM
- 22 Metabolic flux in the Multiple Myeloma Tumor Microenvironment: The Impact of Mitochondrial 1C Metabolism Presented by Celia Berkers, Utrecht University, NETHERLANDS
- 23 Uncovering the intricate crosstalk between Hypoxia and Polyamine Metabolism in Prostate Cancer Presented by Edurne Berra Ramirez, CIC bioGUNE, BRTA, Derio and CIBERONC, Madrid, SPAIN
- 24 Single-cell metabolic multiomics identifies clinically relevant alterations in leukemia stem cells across AML subtypes. Presented by Eleni Besiridou, University Hospital Heidelberg, GERMANY
- 25 Targeting resistance mechanisms in melanoma Presented by Mayra Betancourt Ponce, University of Wisconsin, Madison, WI, USA
- 26 Inhibition of Oxidative Phosphorylation Leads to Immunogenic Cell Death in Ovarian Cancer Presented by Mayra Betancourt Ponce, University of Wisconsin, Madison, WI, USA
- 27 Dietary Histidine controls intestinal stem cell activity, offering a potential protective role against colorectal cancer Presented by Cornelia Biehler, University of Helsinki, FINLAND
- 28 Spatially resolved metabolic heterogeneity in human lung adenocarcinoma Presented by Robert Bielik, Cancer Research UK Scotland Institute, Glasgow, UK
- 29 Severe hypoxia microenvironment in glioblastoma cells and tumors - altered cell metabolism and growth predicted by machine learning Presented by Aleksandra Bienia, Jagiellonian University, Kraków, POLAND
- 30 Active Oxidative Metabolism and Impaired Glyoxalase System Amid Elevated Intracellular Oxidative Stress in Non-Small Cell Lung Cancer shown by immediate alkylation and redox proteomics Presented by Ruth Birner-Gruenberger, TU Wien, Vienna and Medical University of Graz, AUSTRIA
- 31 tRNA wobble editing controls FSP1 expression and dictates ferroptosis sensitivity in lung cancer Presented by Arnaud Blomme, University of Liège, BELGIUM
- 32 Understanding and exploiting the metabolic architecture of CREBBP-deplete DLBCL Presented by James Boncan, Barts Cancer Institute, London, UK

33 ESR1-activating mutations reveal metabolic vulnerabilities in ER+ breast cancer cells  
Presented by Francesca Bonechi, University of Florence, ITALY

34 Autophagy as a critical mediator of drug resistance in Acute Myeloid Leukemia  
Presented by Alexandre BOUDET, CRCT, Toulouse, FRANCE

35 Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms Presented by Matteo Brindisi, IRCCS, Rozzano and Institute for Genetic and Biomedical Research, Milan, ITALY

36 The ribotoxic stress response regulates tumour immune escape via MHC-I transcript decay Presented by Kristin Brown, Peter MacCallum Cancer Centre and University of Melbourne, AUSTRALIA

37 Development of a MULTI-tracer autoradiography research tool in murine orthotopic lung tumors – unraveling the full potential of PET for precision medicine Presented by Morten Busk, Aarhus University Hospital, DENMARK

38 Fatty acid biosynthesis plays a role in lung metastatic niche formation and progression Presented by Weigang Cai, The Francis Crick Institute, London, UK

39 The role of adipocytes in neuroendocrine tumors: molecular and metabolic adaptations Presented by Chiara Calabrese, IRCCS-IRST, Meldola, ITALY

40 **(POSTER SPOTLIGHT)** Non-invasive imaging of carnitine utilisation in non-small cell lung cancer with [18F]fluoromethyl carnitine PET Presented by Ella-May Hards, King's College London, UK

41 Functional Characterization of Metabolic Heterogeneity as a Driver of Tumorigenesis Presented by Jessica Calviello, University of Barcelona, SPAIN

42 Unravelling the role of Integrated Stress Response signalling in metastatic breast cancer bioenergetics Presented by Clara Cardella, Vita-Salute San Raffaele University, Milan, ITALY

43 Identification of lymph node lipidomic and metabolomic biomarkers for breast cancer progression Presented by Alanis Carmona, Harvard T.H. Chan School of Public Health, Boston, MA, USA

44 Mitochondria Cristae Remodeling Promotes Pancreatic Cancer Progression Presented by Alessandro Carrer, University of Padova and VIMM, Padova, ITALY

45 Regulation of p53 by Linked Phosphoinositides: A Novel Signaling Paradigm in Cancer Presented by Noah Carrillo, University of Wisconsin-Madison, USA

46 Distinct Metabolic Signatures in Colorectal Cancer Unveiled Through Integrative multi-omics profiling Presented by Marta Cascante, University of Barcelona and CIBEREHD, National Spanish Health Institute Carlos III, Barcelona, SPAIN

47 RSK4 Regulates Glucose Metabolism in Non-small Cell Lung Cancer. Presented by Peng Chai, Imperial College London, UK

48 Multiple myeloma glutamine addiction favors adipocyte differentiation leading to a pro-tumor bone marrow niche Presented by Martina Chiu, University of Parma, ITALY

49 Tackling oxidative phosphorylation of Glioblastoma Initiating cells' through the specific impairment of transmembrane Chloride Intracellular Channel 1 Presented by Francesca Cianci, Università di Milano, ITALY

50 miR-148b induces mitochondrial dysfunction and inhibits melanoma progression Presented by Martina Coco, University of Torino, ITALY

- 51 miR-214-driven cell metabolism rewiring and melanoma progression Presented by Sara Cozzubbo, University of Torino, ITALY
- 52 Dissecting the metabolic factors that determine metastatic melanoma organotropism Presented by Victor Manuel Cruz Vilchez, CBMSO, CSIC-UAM, Madrid, SPAIN
- 53 Metabolic Reprogramming and Lipid Droplet Accumulation in ccRCC: The Influence of HIF2 Presented by Tamara Cubiella, Institute of Sanitary Research of the Principality of Asturias, and Institute of Oncology of the Principality of Asturias, Oviedo, SPAIN
- 54 C3G as a key regulator of metabolic reprogramming and tumor initiation in glioblastoma Presented by Mateo Cueto-Remacha, Universidad Complutense and IdISSC, Madrid, SPAIN
- 55 Stromal cells and matrix composition dictate cell responses to GOT1 inhibition in pancreatic cancer Presented by Rodrigo Curvello, Monash University, Clayton, AUSTRALIA
- 56 An Artificial Intelligence-Based Clinical-Radiomic Model Enables Treatment Response Prediction in Aggressive B-Cell Lymphomas Presented by Farid Cury Neto, FACSIS and Barretos Cancer Hospital, São Paulo, BRAZIL
- 57 Proteomic assessment of a novel HDAC-6 inhibitor on metabolism. Presented by Cian D'Arcy, Royal College of Surgeons in Ireland, Dublin, IRELAND
- 58 Enhancing Cancer Metabolomics with Bayesian Statistical Models Presented by Katja Danielzik, University of Duisburg-Essen, GERMANY
- 59 Unlocking drug resistance: How cancer-associated fibroblasts drive lipid metabolic changes in ALK-driven lung adenocarcinomas Presented by Ann-Kathrin Daum, DKFZ, DKTK, NCT and DZL, Heidelberg, GERMANY
- 60 Cellular and Metabolic Nature of Hexokinase 2 regulation in meningioma growth Presented by Leandro de Assis, University of Plymouth, UK
- 61 Metabolic interaction between cancer cells and adipocytes in breast cancer. Presented by Carolina Dehesa Caballero, Deutsches Krebsforschungszentrum and University Heidelberg, GERMANY
- 62 Plasma metabolite biomarkers for detection and follow-up of early lung cancer recurrence using NMR-based metabolomics Presented by Elien Derveaux, Hasselt University, BELGIUM
- 63 Mechanistic Insights into HuR-Regulated Aerobic Glycolysis in Triple Negative Breast Cancer (TNBC) Presented by Arundhathi Dev J R, All India Institute of Medical Sciences New Delhi, INDIA
- 64 Metabolic consequences of doxorubicin and docetaxel treatment in breast cancer models Presented by Shaymaa Dib, Weill Cornell Medicine-Qatar, Doha, QATAR
- 65 CREBBP-deplete Small Cell Lung Cancer cells are sensitive to one-carbon metabolism inhibition Presented by Lili Dimitrova, Bart's Cancer Institute, London, UK
- 66 Radiotherapy-induced tumor and stromal cell state regulation in pancreatic ductal adenocarcinoma Presented by Vuk Dinovic, University Hospital Essen and University of Duisburg-Essen, GERMANY
- 67 Multifunctional role of the GATOR1 complex in cisplatin resistance extends beyond mTORC1 regulation Presented by Svetlana Dokudovskaya, Gustave Roussy, Villejuif, FRANCE

68 Different ways to die: Understanding cell death pathways after Ag5 treatment in cancer cells Presented by Blanca Domínguez, Universidade de Santiago de Compostela and Arjuna Therapeutics, Ames, SPAIN

69 Alternative Pathways for Glutamine Addiction in Cancer: The Role the Glutamine Transaminase--Amidase (GTA) Pathway Presented by Thambi Dorai, New York Medical College, Valhalla and Northwell Health System, Sleepy Hollow, NY, USA

70 *Poster withdrawn*

71 Development of SLC16A3 inhibitors through dedicated SLC-focused drug discovery platform Presented by Vojtech Dvorak, Solgate GmbH, Klosterneuburg, AUSTRIA

72 Influences of the anti-diabetic treatment dipeptidyl peptidase-4 (DPP4) inhibitor on radiation response of breast carcinoma cells with different metastatic capacities Presented by Marie Theres Eling, Medical University of Innsbruck, AUSTRIA

73 Identifying metabolic vulnerabilities in chemo-refractory neuroblastoma Presented by Giulia Emanuelli, The Francis Crick Institute, London, UK

74 Dissecting the role of FAM134B mediated ER-phagy in colorectal neoplasia development Presented by Marianna Esposito, TIGEM Telethon Institute of Genetics and Medicine, and SSM Scuola Superiore Meridionale, Naples, ITALY

75 Characterization of cysteine dependency implicates glutathione metabolism as a critical adaptation axis in pancreatic cancer Presented by Chiamaka Ezech, Cornell University, Ithaca, USA

76 Mitochondrial rearrangement driven by cardiolipin depletion enhances drug resistance in lung adenocarcinoma Presented by Simone Falco, University of Bern, SWITZERLAND

77 Regulation of macrophage polarisation in the acidic pancreatic tumour microenvironment Presented by Aruba Farooq, University of Nottingham, UK

78 A novel green molecule containing butyryl species adsorbed to biochar to target the metabolic characteristics of colorectal cancer cells Presented by Laura Fei, University of Florence, ITALY

79 Fructose induces the epithelial-mesenchymal transition program via the epigenetic regulator BRD4 in prostate cancer cells Presented by Luz Flores, Universidad San Sebastián, Santiago, CHILE

80 **IPOSTER SPOTLIGHT** Metabolic Reconfiguration During Disease Progression in Triple-Negative Breast Cancer Presented by Maximilian Krämer, MSNZ, University Hospital Würzburg, GERMANY

81 Hypoxia and HIF2- related -ketoglutarate accumulation as a therapeutic target for reverting macrophage metabolic reprogramming and immune evasion in MASH-related HCC Presented by Beatrice Foglia, University of Turin, ITALY

82 Dissecting the role of mitochondrial oxidative metabolism in ovarian cancer progression and drug response Presented by Laura Formenti, "Mario Negri" Institute for Pharmacological Research, Milan, ITALY

83 Serine-mediated metabolic reprogramming in cancer: SLC1A4, a new therapeutic approach Presented by Benjamin Fourneaux, Cancer research institute of Montpellier, FRANCE

84 Identification of a metabolic alteration that drives radiotherapy resistance in BRCA1;p53-deficient mammary tumors Presented by Paola Francica, University of Bern, SWITZERLAND

- 85 Investigating the subcellular localization of Monocarboxylate Transporter 1 to the nucleus in Endometrial Cancer Presented by Jakub Franczak, The University of Manchester, UK
- 86 BET inhibitors as a precision medicine in Cervical Cancer Presented by Elisa Garde Lapido, Karolinska Institutet, Stockholm, SWEDEN
- 87 RET receptor integrates PDGF signal to regulate breast cancer cell-adipose tissue communication in favor of tumor growth Presented by Albana Gattelli, Ciudad Universitaria C1428EGA CABA, Buenos Aires, ARGENTINA
- 88 Decoding FAM134B function in Colorectal Cancer Presented by Debora Gentile, Telethon Institute of Genetic and Medicine (TIGEM), and Federico II University, Napoli, ITALY
- 89 Deciphering the role of metabolic heterogeneity and plasticity in chemoresistance in ovarian cancer patients Presented by Geraldine Gentric, Institut Curie, PSL Research University, Paris, FRANCE
- 90 Protein Tyrosine Phosphatase Receptor Kappa (PTPRK) regulates glycolysis promoting hepatocyte metabolic reprogramming and hepatocellular carcinoma development in obesity Presented by Eduardo Gilgioni, Université libre de Bruxelles, Brussels, BELGIUM
- 91 Uncovering metabolic and apoptotic vulnerabilities in multiple myeloma Presented by Stephanie Gilmore, RCSI, Dublin, IRELAND
- 92 Early pharmacological profiling of novel metabolism-disrupting molecules directed towards hard-to-treat cancers Presented by Aday González Bakker, Universidad de La Laguna, San Cristóbal de La Laguna, Tenerife Canary Island, SPAIN
- 93 Unveiling the therapeutic potential of PERK pathway inhibition in alcohol-associated aggressive hepatocellular carcinoma Presented by Himanshi Goyal, Post Graduate Institute of Medical Education and research, Chandigarh, INDIA
- 94 Blockade of fatty acid biosynthesis promotes adipotaxis and stimulates the uptake of lipids from adipocytes into ovarian cancer cells Presented by Thomas Grunt, Medical University of Vienna and Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, AUSTRIA
- 95 The cooperation between PI3Kalpha and PI3Kgamma controls metabolic adaptations in pancreatic cancer Presented by Julie Guillemet-Guibert, CRCT, Inserm/CNRS/Université Paul Sabatier, Toulouse, FRANCE
- 96 Synergistic Effects of LDHA Inhibitor FX-11 with Anti-Cancer Drug Library in KRAS-Mutant Cancer Cells Presented by Sabire Guler, Bursa Uludag University, TURKEY
- 97 The dihydropyrimidines as oncometabolite to maintain breast cancer cell aggressiveness Presented by Arata Hayashi, The Hebrew University Hadassah Medical School, Jerusalem, ISRAEL
- 98 Glycolysis- and tricarboxylic acid cycle-related intra-tumoral metabolite profiles correlate with in vivo hyperpolarized lactate imaging in murine epithelial and mesenchymal pancreatic cancer Presented by Irina Heid, Technical University of Munich and NVision Imaging Technologies GmbH, Ulm, GERMANY
- 99 Effects of the L-amino acid oxidase IL4I1 on cancer metabolism Presented by Alessa Luise Henneberg, DKFZ, DKTK, DKFZ and Heidelberg University, GERMANY



- 100 A metabolic crosstalk occurs between human bone marrow adipocytes and prostate cancer cells that promote tumor aggressiveness Presented by Marine Hernandez, Université de Toulouse, FRANCE
- 101 Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase Presented by Katerina Hlozkova, Charles University, Prague, CZECH REPUBLIC
- 102 Growth enhancement in early stage human melanoma cells by proline uptake Presented by Martin Hohenegger, Medical University Vienna, AUSTRIA
- 103 Deregulated Lipid Hydrolysis in Lung Tumors: Implications for Proliferation and Metabolic Reprogramming in Non-Small Cell Lung Cancer Presented by Sophie Honeder, TU Wien, Vienna, AUSTRIA
- 104 Inhibition of RRM1 O-GlcNAcylation suppresses pancreatic cancer via TK1 stabilization-induced replication stress Presented by Chun-Mei Hu, Genomics Research Center, Academia Sinica, Taipei, TAIWAN ROC
- 105 Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Presented by Sanobar Kafeel, University of Campania "Luigi Vanvitelli", Naples, ITALY
- 106 Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors. Presented by Marjolein Kes, Princess Máxima Center for Pediatric Oncology and Utrecht University, NETHERLANDS
- 107 The Anticancer Potential of COX-2 and 5-LOX Inhibitors in Colorectal and Pancreatic Carcinoma Presented by Otilija Keta, University of Belgrade, SERBIA
- 108 Pan-cancer flux balance analysis to characterise tissue specific metabolic alterations Presented by Manas Kohli, Institute of Cancer Research, London, UK
- 109 L-asparaginase modulates response to cystine depletion in acute lymphoblastic leukemia Presented by Matus Kolarik, Charles University, Prague, CZECH REPUBLIC
- 110 Investigating Metabolic Reprogramming in Human Astrocytes and Glioblastoma Invasive Margin Cells Mediated by Human-Brain Derived Extracellular Matrix Presented by Une Kontrimaitė, University of Nottingham, UK
- 111 The mitochondrial phenotype of c-MYC driven tumours Presented by Michael Kossifos, The Francis Crick Institute and UCL, London, UK
- 112 Vitamin B5 as a Bottleneck for Oncogenic Metabolism Presented by Peter Kreuzaler, University of Cologne, GERMANY and The Francis Crick Institute, London, UK
- 113 Metabolic function of mutant p53 in hepatocellular carcinoma Presented by Jelena Krstic, Medical University of Graz and BioTechMed, Graz, AUSTRIA
- 114 Deciphering the role of ABCC1 in squamous cell carcinoma Presented by Veronica La Banca, University of Rome "Tor Vergata", Roma, ITALY
- 115 Metabolic reprogramming with a ketogenic diet as an adjunct to chemotherapy in acute myeloid leukemia: a randomized controlled trial Presented by Maria Lastra Cagigas, The University of Sydney, AUSTRALIA
- 116 Metabolic rewiring in PDAC - NFATc1 mediated pathways unveil novel vulnerabilities for enhanced therapeutic efficacy Presented by Muhammad Umair Latif, University Medical Center Goettingen, GERMANY
- 117 Breast cancer cell lines have different lipidomes related to proliferation and EMT state Presented by Hanneke Leegwater, Leiden University, NETHERLANDS

- 118 UCP2 enhances anti-tumor T cell immune function during colorectal cancer development Presented by Angèle Luby, Université Paris Cité, INSERM, CNRS, Paris, FRANCE
- 119 Transferrin receptor 1 expression in human monocytes from squamous cell carcinoma patients Presented by Renan Lemos da Silva, University of São Paulo, BRAZIL
- 120 **[POSTER SPOTLIGHT]** Genome-wide CRISPR screen identifies C1orf35 as a novel regulator of hepatic lipid metabolism and therapeutic avenue targeting drug resistance in hepatocellular carcinoma Presented by Li Dong, University of Melbourne, AUSTRALIA
- 121 Uncovering the role of the oncometabolite indole-3-pyruvate in liver cancer Presented by Igor Lopes dos Santos, UT Southwestern Medical Center, Dallas, TX, USA
- 122 Multi-Omics and Genome-Scale Metabolic Models Highlight Metabolic Vulnerabilities Tied to FOLFOX Adaptations in Colorectal Cancer Presented by David López, University of Barcelona and CIBEREHD, ISCIII, Madrid, SPAIN
- 123 PHGDH heterogeneity is a key driver of 5-Fluorouracil resistance in colorectal cancer Presented by Giulia Lori, Dept of Experimental and Clinical Medicine, Florence, ITALY
- 124 Exploring metabolic vulnerabilities: Modulating B-vitamins in cancer Presented by Ying Thong Low, Francis Crick Institute, London, UK
- 125 **[POSTER SPOTLIGHT]** The prognostic value of emerging cancer cachexia factor TIMP-1 and its impact on liver metabolism Presented by Damjan Manevski, Technical University of Munich, GERMANY
- 126 Exploring the role of L-type amino acid transporters as a therapeutic and imaging target in Myc-driven breast cancer Presented by Asad Mahmood, Francis Crick Institute, London, UK
- 127 The role of LIPG in cholesterol homeostasis in breast cancer Presented by Zhwan Mahmoud, Leibniz-Institute for working environment and human factors, Dortmund, GERMANY
- 128 Metabolic heterogeneity in Glioblastoma, as defined by spectroscopic MRI, drives basal and post-irradiation metabolic profiles of Glioblastoma Stem Cells Presented by Tom Maillet, UMR1037 Cancer Research Center of Toulouse, FRANCE
- 129 Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy Presented by Avishy Maliach, Tel Aviv University, ISRAEL
- 130 **[POSTER SPOTLIGHT]** Ketogenic diet targets SCD-triggered lipid homeostasis and therapy resistance in FLT3-ITD acute myeloid leukemia Presented by Léa Goupille, CRCT and CREFRE, Toulouse, FRANCE
- 131 Role of the senescent stroma-derived glutamine in the aggressiveness of prostate and ovarian cancer cells Presented by Caterina Mancini, Dept of Experimental and Clinical Medicine, Florence, ITALY
- 132 Impact of gut inflammation, microbiota, and peripheral serotonin on glioblastoma development and therapeutic resistance Presented by Océane Martin, University Bordeaux, CNRS IBGC UMR 5095, Bordeaux, FRANCE
- 133 BACE2 regulates lipid transporters tuning lipid homeostasis in cancer Presented by Vittoria Matafora, IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, ITALY

- 134 Metabolic reprogramming by SLC25A1 inhibition increases radiosensitivity and impairs DNA repair in cancer cells. Presented by Johann Matschke, University Hospital Essen, University of Duisburg-Essen and DKTK, Essen, GERMANY
- 135 Mitophagy and cancer: role of BNIP3/BNIP3L as energetic drivers of stemness features, ATP production, proliferation, and cell migration Presented by Marta Mauro Lizcano, University of Salford, Manchester, UK
- 136 Breast cancer cells surviving executioner caspase activation, anastasis, are vulnerable to ferroptosis due to ZEB1-mediated down regulation of GPX-4 Presented by Paul McDonald, BC Cancer Research Institute, Vancouver, CANADA
- 137 A rise in double-strand breaks sensitizes tumours to oxidative metabolism inhibitors Presented by Ferran Medina-Jover, Universitat de Barcelona, L'Hospitalet del Llobregat, SPAIN
- 138 Mitochondrial Metabolism and Oxidative Stress in Obesity-Related Inflammation in Luminal Breast Cancer: Implications for Mammosphere Formation and Treatment Resistance Presented by Lucas Melguizo, Universitat de les Illes Balears, Palma, Islas Baleares, SPAIN
- 139 Plasma metabolite biomarkers for improved lung cancer diagnosis in patients with solitary pulmonary nodules Presented by Jill Meynen, Hasselt University, BELGIUM
- 140 ROS induction as a strategy to target persister cancer cell metabolism Presented by Ossia Eichhoff, University Hospital Zurich, SWITZERLAND
- 141 Resolving the metabolic signature of glioblastomas – one cell at a time Presented by Wojciech Michno, Uppsala University, SciLifeLab, SWEDEN
- 142 Glucose impacts onto the reciprocal reprogramming between mammary adipocytes and cancer cells. Presented by Teresa Migliaccio, University of Naples "Federico II" (DiSMet-UniNa), ITALY
- 143 Role of MYC and Cyclin D1 in metabolism of Breast Cancer Stem Cells Presented by Zahra Moftakhar, University of Salford, UK
- 144 Modeling of metabolic reprogramming in triple negative breast cancer Presented by Ilana MOREAU, Radboud University, Nijmegen, NETHERLANDS
- 145 Functional Implications of ER Localization in Invasive Ductal and Lobular Carcinomas Presented by Pere Miquel Morlà Barceló, Universitat de les Illes Balears, Palma, SPAIN
- 146 Targeting Thymidylate Synthase (hTS) suppresses colorectal cancer cell growth by inducing DNA damage and apoptosis Presented by Maria Gaetana Moschella, UNIMORE, Modena. Italy/Emilia Romagna, ITALY
- 147 Functional synapses between small cell lung cancer and glutamatergic neurons Presented by Elisa Motori, University of Cologne, GERMANY
- 148 Targeting polyamine uptake in liver cancer Presented by Christoph Müller, University of Basel, SWITZERLAND
- 149 Differential regulation of mTORC2 signalling by Type 1 and Type II calreticulin (CALR) mutations driving myeloproliferative neoplasm Presented by Saadia Naseer, Indian Institute of Technology, New Delhi, INDIA
- 150 The Importance of Caveolin-1 in Prostate Cancer Metabolism: Tumour Suppressive and Oncogenic Roles Presented by Jiří Navrátil, Masaryk University, Brno, CZECH REPUBLIC

151 WEE1 inhibition couples replication stress to glycolytic depression and metabolic reprogramming. Presented by Theodore Nguyen, Fox Chase Cancer Center and Drexel University, Philadelphia, PA, USA

152 Targeting KRAS selectively induce metabolic reprogramming in pancreatic cancer Presented by Zeribe Nwosu, Cornell University and Weill Cornell Medical College, New York City, USA

153 Cold-pressed lingonberry (*Vaccinium vitis-idaea* L.) extract inhibits the proliferation of oral carcinoma cells by targeting glycolytic capacity Presented by Tuulia Onali, Helsinki University, FINLAND

154 The role of SIRT3 in breast cancer and tamoxifen resistance Presented by Yaiza Pacior Pampin, Czech Academy of Sciences, Vestec, and Charles University, Prague, CZECH REPUBLIC

155 Knock-out of CD147 reveals significant differences in mitochondrial metabolism and invasive potential in head and neck squamous cell carcinoma cells Presented by Barbora Peltanová, Masaryk University, Brno, CZECH REPUBLIC

156 Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis Presented by Lizbeth Perez-Castro, University of Texas Southwestern Medical Center, Dallas, USA

157 Unravelling Metabolic Vulnerabilities in Mesothelioma Presented by Silvia Plans Marin, IDIBELL, Hospitalet de Llobregat, SPAIN

158 CD47 regulates cellular and metabolic plasticity in glioblastoma Presented by Ruhi Polara, Centre for Cancer Biology, Adelaide, AUSTRALIA

159 Metabolic alterations in tamoxifen-resistant cells Presented by Petra Potomova, Czech Academy of Sciences, Vestec, and Charles University, Prague, CZECH REPUBLIC

160 **[POSTER SPOTLIGHT]** Epstein Barr virus-induced IDO1 drives lymphomagenesis via NAD de novo synthesis Presented by Bojana Mueller, University of Zurich, SWITZERLAND

161 The role of Rank signaling in metabolic reprogramming in postmenopausal breast cancer Presented by Macarena Pozo Morales, CNIO, Madrid, SPAIN

162 Spatial metabolomics reveals nerve-induced metabolic rewiring in pancreatic cancer Presented by Amandine Prats, Pharmacology Institute Heidelberg Medical Faculty, and European Molecular Biology Laboratory, GERMANY

163 Repurposing anti-diabetic drugs in cancer: metformin anti-cancer action targets the metabolic characteristics of metastatic adrenocortical carcinoma Presented by Arianna Pia Propato, University of Florence, ITALY

164 Chemoresistance in breast cancer: The role of NOTCH3 signalling Presented by Jana Psotová, Czech Academy of Sciences, Vestec, and Charles University, Prague, CZECH REPUBLIC

165 Harnessing the Role of BRCA1 Deficiency in Breast Cancer Metabolic Rewiring Presented by Leonor Puchades-Carrasco, Instituto Investigación Sanitaria La Fe, Valencia, SPAIN

166 Multi-omics analysis identifies LCK and PPARG as key players of invasiveness in human oral cancer Presented by Jonas Pyko, Martin Luther University Halle-Wittenberg, Halle (Saale), GERMANY

- 167 LUBAC and OTULIN Regulate AMPK Signalling and Cellular Metabolism in Response to Energetic Stress Presented by Camilla Reiter Elbaek, Technical University of Denmark, Kgs. Lyngby, DENMARK
- 168 NIPBL is a novel 3D-specific tumour suppressor that defines multidrug resistance Presented by Lakshmi Rajput, Barts Cancer Institute, London, UK
- 169 Decreased food intake drives hyper-sensitivity to insulin in cancer cachexia Presented by Steffen Raun, University of Copenhagen, DENMARK
- 170 A feedforward loop between ACLY and MYC supports T-ALL progression in vivo Presented by Victoria da Silva Diz, Rutgers University, New Brunswick, NJ, USA
- 171 Pyruvate Dehydrogenase Kinases as Therapeutic Targets in Pediatric Neuroblastoma Presented by Rafael Pulido, Biobizkaia Health Research Institute/ CIBERER, Barakaldo, SPAIN
- 172 Interaction with hepatic stellate cells drives metabolic rewiring and hypoxia-inducible factor (HIF)-1-dependent proliferation in hepatocellular carcinoma cells Presented by Demi Rijlaarsdam, Utrecht University, NETHERLANDS
- 173 Deciphering mitochondrial metabolism as a target for metastatic melanoma Presented by Alba Roca-Portoles, Centro de Biología Molecular Severo Ochoa, and Universidad Autónoma, Madrid, SPAIN
- 174 Alternative pathway of aspartate synthesis sustains tumor growth Presented by Jakub Rohlena, Czech Academy of Sciences, Vestec, Prague, CZECH REPUBLIC
- 175 Investigating the metabolic role of ATM and its contribution to ATR inhibitor drug resistance Presented by Hannah Rouse, Barts Cancer Institute, London, UK
- 176 Crosstalk Between Adipocytes and Cancer Stem Cells Enhances Pancreatic Cancer Aggressiveness Presented by Alba Royo García, IIS Aragón, Zaragoza, SPAIN
- 177 Macrophage metabolic programming facilitates enhanced immune response in pancreatic cancer Presented by Shannon Russell, University of Oxford, UK
- 178 Targeting metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): lactate transporters MCT1 and MCT4 in the crosshair for precision therapy Presented by Martin Sadowski, University of Bern, SWITZERLAND
- 179 Co-targeting oncogenic and epigenetic pathways in castration-resistant prostate cancer (CRPC) Presented by Rhea Sahu, Harvard University, and Brigham and Women's Hospital, Boston, MA, USA
- 180 Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma Presented by Lourdes Sainero Alcolado, Karolinska Institutet, Stockholm, SWEDEN
- 181 Metabolic Characterization Of DLBCL Molecular Subtypes Presented by Sara Salazar Ortego, Severo Ochoa Centre for Molecular Biology, CSIC-UAM, Madrid, SPAIN
- 182 Exploring the Role of Horizontal Mitochondria Transfer in Cancer Presented by Jaime San-Juan-Guardado, Health Research Institute of the Principality of Asturias, and University of Oviedo, SPAIN
- 183 Targeting glycolysis boosts immunotherapy efficacy in poor-prognosis GSNOR-deficient colorectal cancer Presented by María Teresa Sánchez Montero, IMIBIC, Cordoba, SPAIN

- 184 Ligand-dependent activation of PPAR- $\delta$  in response to starvation and pseudostarvation signals induces a prometastatic program in pancreatic cancer  
Presented by Patricia Sancho, IIS Aragón, Zaragoza, SPAIN, and Barts Cancer Institute, Queen Mary University of London, UK
- 185 Heteroplasmy levels of complex I ND5 mutations affect migration in renal cancer cells  
Presented by Debarati Sanyal, University of Cologne, GERMANY
- 186 Dual inhibition of PFKFB3 and ODC1 exhibits enhanced antiproliferative effect on pancreatic cancer cells  
Presented by Aybike Sarioglu Bozkurt, Bursa Uludag University, Nilufer/Bursa, TURKEY
- 187 Metformin avoids the senescence-associated secretory phenotype (SASP) promoted by obesity-related inflammation in T47D luminal breast cancer cell line  
Presented by Jorge Sastre Serra, Universitat de les Illes Balears, Palma, SPAIN, and Instituto de Salud Carlos III, Madrid, SPAIN
- 188 Electron transport chain leakage as a key molecular mechanism underpinning MYC-induced apoptosis  
Presented by Kianoosh Sateri, Barts Cancer Institute, London, UK
- 189 Targeting mutant isocitrate dehydrogenase 2 Acute Myeloid Leukemias leveraging fructose metabolism  
Presented by Angela Maria Savino, University of Milano-Bicocca, ITALY, and Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 190 Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards the hexosamine biosynthesis  
Presented by Laura Bozal-Basterra, CIC bioGUNE, Derio, and CIBERONC, Madrid, SPAIN
- 191 MetaProViz R-package reveals novel metabolic patterns in kidney cancer  
Presented by Christina Schmidt, University Clinics Heidelberg, GERMANY, and EMBL-EBI, Cambridgeshire, UK
- 192 PDK3: Targeting Metabolic Reprogramming in Melanoma to Overcome Therapy Resistance  
Presented by Caroline Miho Shibuya, Hospital de Câncer de Barretos, SP, BRAZIL
- 193 STEAP1-STEAP2 Interaction: Modulating Iron Levels and Metabolic Adaptations in Ewing Sarcoma  
Presented by Taras Shyp, The University of British Columbia and BC Cancer Research Institute, Vancouver, CANADA
- 194 Bone marrow stromal cells enhance differentiation of acute myeloid leukemia cells induced by pyrimidine synthesis inhibitors  
Presented by Tomislav Smoljo, University of Zagreb School of Medicine, CROATIA
- 195 Immunomodulatory effect of metabolic priming in multipotent mesenchymal stromal cells  
Presented by Katarína Smolková, Institute of Physiology CAS, Prague, CZECH REPUBLIC
- 196 Transcriptomic analysis of MDA-MB-231 cell line treated with 2-deoxy-D-glucose alone or co-treated with metformin: an in vitro model of cancer metastasis after reattachment  
Presented by Tadeja Snedec, University of Ljubljana, SLOVENIA
- 197 Analysis of metabolic signature in response to cytokine priming of multipotent mesenchymal stromal cells  
Presented by Jitka Špačková, Czech Academy of Sciences, Prague, CZECH REPUBLIC
- 198 Targeting glutamine catabolism in Myc driven mammary gland tumours  
Presented by Amy Spicer, Francis Crick Institute and Imperial College London, UK



199 Nitrogen isotope ratios in tumor tissues: a new perspective on cancer diagnosis and cell metabolism Presented by Marietta Straub, Lausanne University Hospital and University of Lausanne, SWITZERLAND, and Max Planck Institute for Chemistry, Mainz, GERMANY

200 **[POSTER SPOTLIGHT]** Increased glucose uptake associated with the Warburg effect generates NADH to maintain an optimal NAD<sup>+</sup>/NADH ratio to support cancer cell proliferation Presented by Muhammad Munim, Koch Institute for Integrative Cancer Research and Massachusetts Institute of Technology, Cambridge, MA, USA

201 Allosteric inhibitor of mitochondrial glutamine transporter disrupts cancer cell metabolism Presented by Yulseung Sung, Yonsei University, Incheon, SOUTH KOREA

202 Reduced purine biosynthesis flux as an essential component of the EMT program Presented by Mayur Tanna, The Hebrew University, Jerusalem, ISRAEL

203 Identifying key metabolic pathways that contribute to metastasis of breast cancer to the lung Presented by Josep Tarrago Celada, The Francis Crick Institute, London, UK

204 Investigating the impact of obesity on breast cancer progression and the therapeutic potential of metformin Presented by Danielle Tongue, University of Southampton, UK

205 Secreted spermidine synthase reveals a paracrine role for PGC1-induced growth suppression in prostate cancer Presented by Veronica Torrano Moya, University of the Basque Country, Leioa, and CIBERONC, Madrid, SPAIN

206 Single-cell lipidomics identifies the phenotypic states in PDAC Presented by Marija Trajkovic-Arsic, University Hospital Essen, and DKTK, Essen, GERMANY

207 Prostaglandin E2-EP4 signalling drives metabolic reprogramming in colorectal tumour cells Presented by Elysia Traynor, University of Bristol, UK

208 Homoplasmic mitochondrial DNA variants as potential positive prognostic biomarker in ovarian cancer patients Presented by Chiara Trento, University of Padova, ITALY

209 Mitochondrial efficiency and activity are required for proliferation of glioblastoma multiforme cells Presented by Minou Tsujishita, Imperial College London, UK

210 The role of CD44 protein in the bone marrow microenvironment-mediated metabolic remodeling of chronic myeloid leukemia Presented by Laura Turos-Korgul, Nencki Institute of Experimental Biology, PAS, Warsaw, POLAND

211 Functional genomics screenings identify potential metabolic dependencies in KRAS/TP53 double mutant non-small cell lung cancer Presented by Júlia Urgel i Solas, Center for Genomic Regulation, and Universitat Pompeu Fabra, Barcelona, SPAIN

212 Hypoxia changes lipid metabolism in advanced Prostate Cancer Presented by Kalle Vålitalo, Tampere University, FINLAND

213 Reprogramming in MYCN amplified Neuroblastoma cell lines reveals metabolic vulnerabilities in Serine Biosynthesis Pathway Presented by Marieke van de Mheen, Princess Máxima Center, Utrecht, and Amsterdam UMC, NETHERLANDS

214 Proteome and metabolome analysis uncovered new mechanisms for the tumor suppressor role of PATZ1 in anaplastic thyroid cancer Presented by Roberta Veglia Tranchese, National Research Council, Naples, ITALY

- 215 Exploring Glutamine-Dependent Metabolic Pathways and Immune Modulation in MYC-Driven Tumours Presented by Sharavan Vishaan Venkateswaran, The Francis Crick Institute, London, UK
- 216 Nuclear metabolism in the control of DNA methylation in tumour hypoxia. Presented by Roxane Verdikt, KULeuven, Leuven, BELGIUM
- 217 Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma Presented by Giulio Verna, Azienda USL-IRCCS di Reggio Emilia, ITALY
- 218 Studies of cancer cachexia in human iPSC-derived organoids Presented by Katharina Vestre, University of Oslo and Oslo University Hospital, NORWAY
- 219 Effects of atovaquone in targeting metabolism in a 3D model of high-grade serous ovarian carcinoma (HGSOC) Presented by Maria Virumbrales-Munoz, University of Wisconsin-Madison, USA
- 220 **[POSTER SPOTLIGHT]** Targeting mitochondria to mitigate chemotherapy-induced bone marrow dysfunction Presented by Tim van Tienhoven, Erasmus Medical Center, Rotterdam, NETHERLANDS
- 221 Differentiation of Acute Myeloid Leukemia Cells Induced by AICAr: The Role of Nucleoside Availability, RNR Activity, and Wee1 Presented by Dora Višnjić, University of Zagreb, CROATIA
- 222 Involvement of the sympathetic and adrenergic system in the progression of cancer cachexia Presented by Eva Carlotta von Gablenz, Cold Spring Harbor Laboratory, NY, USA, and Ruprecht-Karls-University, Heidelberg, GERMANY
- 223 Reprogramming of Lipid Metabolism in Postmenopausal Breast Cancer Patients Undergoing Aromatase Inhibitor Therapy Presented by Vesna Vucic, University of Belgrade, SERBIA
- 224 Glutamine metabolism antagonist may overcome treatment resistance by induction of DNA damage signaling and DSBs Presented by Tian-Li Wang, Johns Hopkins University School of Medicine, Baltimore, USA
- 225 Ketogenic diet enhances the anti-tumor effect of mifepristone in a breast cancer mouse model Presented by Daniela Weber, University Hospital of the Paracelsus Medical University, Salzburg, AUSTRIA
- 226 Mimicking Fasting in vitro: A Metabolically Defined Cell Culture Medium for Cancer Research Presented by Theresia Weiermair, Medical University of Graz, AUSTRIA
- 227 RIPK4 knockout alters A375 melanoma cells bioenergetics Presented by Norbert Wroński, Jagiellonian University, Kraków, POLAND
- 228 **[POSTER SPOTLIGHT]** The contribution of obesity to castration resistance in prostate cancer Presented by Amaia Zabala, CICBIOGUNE, Bizkaia and CIBERONC, Madrid, SPAIN
- 229 Rebalancing Systemic and Cellular Energy Dysmetabolism In Chronic Lymphocytic Leukaemia Through Exercise Training Presented by Uzma Zaheer, University of Surrey, Guildford, UK
- 230 Targeting wild-type IDH1 sensitizes homologous recombination proficient pancreatic cancer to PARP inhibition Presented by Mehrdad Zarei, Case Western Reserve University, and University Hospitals Cleveland Medical Center, Cleveland, USA

231 Salinomycin Alters Cellular Lipid Metabolism in Lymphoma Cells Presented by Aleksandra Zdanowicz, Medical University of Warsaw, POLAND

232 Effects of NISCH agonist rilmenidine on targeted metabolomics of TCA cycle in PDAC Presented by Kristina Živić, Institute for Oncology and Radiology of Serbia, Belgrade, SERBIA

233 Triglyceride Dynamics Between Adipocytes and Cancer Cells in Cancer Cachexia Presented by Jelena Zurkovic, LIMES Institut, Bonn, GERMANY

234 Genomic Deletion of PFKFB2 Induces Vulnerability to GSK3 Inhibition in Pancreatic Cancer Cells Presented by Ahmet Kahraman, Bursa Uludag University, TURKEY

235 Targeting the Glycolytic Pathway to Overcome Resistance to BCR signaling inhibitors in Diffuse Large B Cell Lymphoma Presented by Antonia-Eugenia Angeli-Terzidou, UKD, Düsseldorf and UKHD, Heidelberg, GERMANY

236 The expression of VEGFR2R1032Q induces metabolic reprogramming of melanoma cells Presented by Stefania Mitola, The Mechanobiology Research Center, UNIBS and Università degli Studi di Brescia, ITALY

**Communication.  
Collaboration.  
Community.**

# EACR

European Association  
for Cancer Research



**NOT A MEMBER  
YET? JOIN NOW**

**Apply for funding  
to develop your  
research &  
expand  
your  
horizons**



**Benefit from  
member  
registration  
rates at EACR  
events**

**Join our online  
networking  
events**



**Build new  
connections  
with our 'Find a  
Collaborator'  
tool**

**Search  
the EACR  
Member  
Network  
and message  
other members**



**Share your  
perspective: write  
for The Cancer  
Researcher  
magazine**

**Access  
our free  
expert  
webinars on  
research &  
careers**



**Stay informed  
with regular  
updates on  
news, jobs &  
conferences**

**Volunteer for  
our Ambassador  
Programme or  
committees**

# EACR on-site team



**Chris Iliffe**  
Conference Officer



**Kathryn Wass**  
Programmes Manager



**Jane Smith**  
Chief Executive Officer




**Fiona Craighead**  
Finance Manager

## Conference dinner

### Optional Ticketed Event, Wednesday 09 October, 20:00 - SOLD OUT

The Conference Dinner will take place at Kafe Antzokia's Restaurant. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment. After dinner, we will enjoy music and dancing with a live DJ.

Kafe Antzokia's Restaurant: Done Bikendi Kalea, 2, 48001 Bilbo, Bizkaia, Spain



## EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the Association to develop important initiatives.

